Pemetrexed prolongs survival in patients with malignant pleural mesothelioma or non-small-cell lung cancer

被引：0
|
作者：
不详
机构：
来源：
Drugs & Therapy Perspectives | 2005年 / 21卷 / 10期
关键词：
D O I：
10.2165/00042310-200521100-00001
中图分类号：
学科分类号：
摘要：
Pemetrexed is a multi-targeted antifolate that inhibits DNA and RNA synthesis. It is used, with cisplatin, in the treatment of malignant pleural mesothelioma (MPM) in patients who are not candidates for surgery and also as second-line monotherapy in locally advanced or metastatic non-small-cell lung cancer (NSCLC). Pemetrexed has favourable tolerability when supplemented with folic acid and cyanocobalamin (vitamin B12). It is clinically active against both MPM and NSCLC, with activity non-inferior to docetaxel in treating refractory or recurrent NSCLC and, with concomitant cisplatin, superior efficacy to single-agent cisplatin in treating unresectable MPM. © 2005 Adis Data Information BV. All rights reserved.
引用
收藏
页码：1 / 4
页数：3
相关论文
共 50 条
  • [1] Pemetrexed in the treatment of non-small-cell lung cancer and malignant pleural mesothelioma
    Kowalski, Dariusz M.
    Krawczyk, Pawel
    Jaskiewicz, Piotr
    Badurak, Pawel
    Krzakowski, Maciej
    ONCOLOGY IN CLINICAL PRACTICE, 2011, 7 (06): : 292 - 300
  • [2] Maintenance therapy with pemetrexed in non-small-cell lung cancer: Impact on survival
    Vaz, Daniel
    Campainha, Sergio
    Antunes, Ana
    Conde, Sara
    Barroso, Ana
    EUROPEAN RESPIRATORY JOURNAL, 2015, 46
  • [3] Alvopem® (pemetrexed) safety assessment in patients with non-small cell lung cancer or malignant pleural mesothelioma: a post-marketing surveillance
    Sharareh Seifi
    Babak Salimi
    Zahra Esfahani Monfared
    Cyrus Sabahi
    Hamidreza Kafi
    Adnan Khosravi
    Journal of Pharmaceutical Policy and Practice, 16
  • [4] Alvopem® (pemetrexed) safety assessment in patients with non-small cell lung cancer or malignant pleural mesothelioma: a post-marketing surveillance
    Seifi, Sharareh
    Salimi, Babak
    Monfared, Zahra Esfahani
    Sabahi, Cyrus
    Kafi, Hamidreza
    Khosravi, Adnan
    JOURNAL OF PHARMACEUTICAL POLICY AND PRACTICE, 2023, 16 (01)
  • [5] The place of pemetrexed in the management of non-small-cell lung cancer patients
    Tomasini, Pascale
    Greillier, Laurent
    Khobta, Nataliya
    Barlesi, Fabrice
    EXPERT REVIEW OF ANTICANCER THERAPY, 2013, 13 (03) : 257 - 266
  • [6] RENAL TOXICITY OF PEMETREXED IN PATIENTS WITH NON-SMALL-CELL LUNG CANCER
    Inoue, Y.
    Karayama, M.
    Ito, Y.
    Kusagaya, H.
    Matsuura, S.
    Nakamura, Y.
    Inui, N.
    Suda, T.
    ANNALS OF ONCOLOGY, 2013, 24 : 81 - 81
  • [7] Pemetrexed in the treatment of non-small-cell lung cancer
    Cash, R.
    Dangoor, A.
    LUNG CANCER, 2015, 87 : S27 - S27
  • [8] Pemetrexed in advanced non-small-cell lung cancer
    Fuld, Alexander D.
    Dragnev, Konstantin H.
    Rigas, James R.
    EXPERT OPINION ON PHARMACOTHERAPY, 2010, 11 (08) : 1387 - 1402
  • [9] Pemetrexed for the treatment of non-small-cell lung cancer
    Manegold, Christian
    Schmid-Bindert, Gerald
    Pilz, Lothar R.
    EXPERT REVIEW OF ANTICANCER THERAPY, 2009, 9 (09) : 1195 - 1209
  • [10] Bevacizumab, When Added To Pemetrexed/platinum, Prolongs Survival In Previously Untreated Patients With Advanced Non-Squamous Non-Small-Cell Lung Cancer In Japan
    Mouri, A.
    Arimoto, Y.
    Takeoka, S.
    Honma, C.
    Fukusumi, M.
    Hamamoto, Y.
    Kamimura, M.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2014, 189
12345